Patents Examined by Jason A Deck
  • Patent number: 11633370
    Abstract: Methods and compounds for use in promoting survival of at least one eukaryotic cell, wherein the compounds are effective as gamma-ketoaldehyde scavengers.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: April 25, 2023
    Assignee: Vanderbilt University
    Inventors: L. Jackson Roberts, II, Thuy T. Nguyen
  • Patent number: 11622965
    Abstract: The present disclosure provides methods of treating lymphoid malignancies such as B cell malignancies using a BTK inhibitor in the described therapeutic regimens.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 11, 2023
    Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.
    Inventor: Wei He
  • Patent number: 11617748
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
    Type: Grant
    Filed: July 21, 2020
    Date of Patent: April 4, 2023
    Assignees: Universite de Paris, Assistance Publique—Hopitaux de Paris
    Inventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
  • Patent number: 11612662
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: March 28, 2023
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • Patent number: 11607411
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: March 21, 2023
    Assignee: AbbVie Inc.
    Inventors: Ana Paula Machado De Lacerda, Jose Jeffrey V. Enejosa, Aileen L. Pangan, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
  • Patent number: 11607399
    Abstract: A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: March 21, 2023
    Inventors: Todd W. Chappell, Keith A. Johnson
  • Patent number: 11596151
    Abstract: An emulsifiable concentrate may include: an aminoindane amide having the structure of formula (I); and an amide having the structure of formula (II); wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, and n are as defined herein, as well as to formulations containing the same, and to methods of their preparation and use for treatment and protection of agricultural crops.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 7, 2023
    Inventors: Robbie Moss Haines, Charlie James Flood, Hong Zhang, David Bird, Laibin B. Yan, Frank J. Zawacki, Claudio Dacarro, Elisa Galimberti, Ilenia Mazzali
  • Patent number: 11590096
    Abstract: In one aspect, use of 1-palmitoyl-2-linoleoyl-3-acetylglycerol (PLAG) for treating or preventing acute radiation syndrome is provided.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: February 28, 2023
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki Young Sohn, Sun Young Yoon
  • Patent number: 11590136
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: February 28, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Patent number: 11590109
    Abstract: Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 28, 2023
    Inventors: Ke Xu, Honglin Li, Yufang Xu, Zhenjiang Zhao, Lili Zhu, Wenlin Song, Yi Tong
  • Patent number: 11576910
    Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 14, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Narimon Honarpour, Fady Malik
  • Patent number: 11564922
    Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: January 31, 2023
    Assignee: AbbVie Inc.
    Inventors: Aileen L. Pangan, Roopal B. Thakkar, Steven Jungerwirth, Ana Paula Machado De Lacerda, Anne M. Robinson, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder, Wen Zhou
  • Patent number: 11555009
    Abstract: The invention provides 2-(substituted phenylhetero) aromatic formate FTO inhibitors, a preparation method thereof, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted phenylhetero) aromatic formate compound represented by the following formula (I), and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, which can be used as an FTO targeting inhibitor for treating diseases associated with FTO targets, including obesity, metabolic syndrome (MS), type 2 diabetes (T2D), Alzheimer's diseases, and cancers such as breast cancers, small-cell lung cancers, human bone marrow rhabdomyosarcoma, pancreatic cancer, malignant glioblastoma and the like.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 17, 2023
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Caiguang Yang, Yue Huang, Ze Dong, Tao Zhang, Hongjiao Xu
  • Patent number: 11553712
    Abstract: The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: January 17, 2023
    Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventor: Sami Chtourou
  • Patent number: 11548860
    Abstract: The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compounds have the formula: [Chem.
    Type: Grant
    Filed: October 22, 2016
    Date of Patent: January 10, 2023
    Assignee: MANGOSUTHU UNIVERSITY OF TECHNOLOGY
    Inventor: Njabulo Joyfull Gumede
  • Patent number: 11542247
    Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: January 3, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Diego Fernando Domenico Broggini, Filip Albert C Cuyckens, Steven Anna Hostyn, Russell Mark Jones, Olivier Alexis Georges Querolle, Wim Vermeulen
  • Patent number: 11534437
    Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions caused by radiation exposure such as RIGS, enteritis, mucositis, e.g., oral mucositis, and proctitis by the administration of compound 512, or an analog thereof.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: December 27, 2022
    Assignee: BCN Biosciences L.L.C.
    Inventor: Andrew J. Norris
  • Patent number: 11524930
    Abstract: The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R1 is H, F or OH; R2 is C5 alkyl, C6 alkyl, C5 alkenyl, C6 alkenyl, C(O)—(CH2)n—CH3 or CH(OH)—(CH2)n—CH3 wherein n is 3 or 4; R3 is H, F, OH or CH2Ph; R4 is H, F or OH; Q is 1) (CH2)mC(O)OH wherein m is 1 or 2, 2) CH(CH3)C(O)OH, 3) C(CH3)2C(O)OH, 4) CH(F)—C(O)OH, 5) CF2—C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: December 13, 2022
    Assignee: LIMINAL BIOSCIENCES LIMITED
    Inventors: Boulos Zacharie, Shaun Abbott, Lyne Gagnon, Pierre Laurin, Brigitte Grouix
  • Patent number: 11517552
    Abstract: A method for treating psoriasis including the steps of applying an isothiocyanate functional surfactant to an area affected by psoriasis, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: December 6, 2022
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 11497720
    Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram negative bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: November 15, 2022
    Assignee: SEPTEOS
    Inventor: Nicolas Tesse